Pompe Disease: Modified ERTs Not Superior to Standard of Care
Physician's Weekly,
Despite this, benefits may be clinically…
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
Overview of attention for article published in Lancet Neurology, December 2021
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (96th percentile)
-
High Attention Score compared to outputs of the same age and source (84th percentile)
Mentioned by
- news
- 2 news outlets
- blogs
- 1 blog
- policy
- 1 policy source
- 20 X users
- patent
- 2 patents
- guideline
- 2 clinical guideline sources
Readers on
- mendeley
- 159 Mendeley